Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD-CAR-1 for Relapsed/Refractory CD19+ Lymphoid Disease
NCT03676504Phase 2Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Sep 2018
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of HD-CAR-1 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and 2 more (3 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Safety of CD19.CAR T cell administration at 90 days and Feasibility of CD19.CAR T cell manufacturing at 45 days. Started Sep 2018; status: recruiting.
02
Drugs
HD-CAR-1
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03676504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676504.